DAVID B SOLIT, MD
Osteopathic Medicine at York Ave, New York, NY
License number
New York 210115
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
1275 York Ave, New York, NY 10021
Phone
(212) 639-2000
Personal information
See more information about DAVID B SOLIT at radaris.comName
Address
Phone
10 E End Ave APT 18C, New York, NY 10075
New York, NY
10 E End Ave, New York, NY 10021
10 End Ave, New York, NY 10021
10 End Ave, New York, NY 10001
Organization information
See more information about DAVID B SOLIT at bizstanding.comDavid B Solit MD
353 E 68 St, New York, NY 10065
Categories:
Physicians & Surgeons
Phone:
(646) 422-4459 (Phone)
Professional information
David B Solit, New York NY
Specialties:
General Practice, Internal Medicine, Medical Oncology, Hematology & Oncology
Work:
Memorial Sloan-Kettering
1275 York Ave, New York, NY 10065
1275 York Ave, New York, NY 10065
Education:
University of Pennsylvania(1995)
Dr. David Solit, New York NY - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
Memorial Sloan Kettering Cncr
1275 York Ave, New York 10065
(646) 888-4233 (Phone)
1275 York Ave, New York 10065
(646) 888-4233 (Phone)
Certifications:
Internal Medicine, 1998, Medical Oncology, 2001
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Memorial Sloan Kettering Cncr
1275 York Ave, New York 10065
Memorial Sloan - Kettering Cancer Center
1275 York Ave, New York 10065
1275 York Ave, New York 10065
Memorial Sloan - Kettering Cancer Center
1275 York Ave, New York 10065
Education:
Medical School
University Of Pennsylvania School Of Medicine
Graduated: 1995
University Of Pennsylvania School Of Medicine
Graduated: 1995
Methods And Compositions For The Detection Of Drug Resistant Braf Isoforms
US Patent:
2012030, Nov 29, 2012
Filed:
May 24, 2012
Appl. No.:
13/480050
Inventors:
Neal ROSEN - Englewood NJ, US
Poulikos Poulikakos - New York NY, US
David Solit - New York NY, US
Poulikos Poulikakos - New York NY, US
David Solit - New York NY, US
International Classification:
C12Q 1/68
US Classification:
435 611, 435 612
Abstract:
The present invention provides methods and compositions for the detection of novel BRAF splice variants that mediate resistance to BRAF and/or pan-RAF inhibitors. In particular, the invention provides PCR primer(s) to be used in the disclosed methods of detection. In some embodiments, the compositions and methods of the present invention are used to predict resistance to BRAF and/or pan-RAF inhibitors in a subject suffering from or suspected of having cancer and further provides alternative treatment strategy(ies) for a subject, predicted to be resistant to BRAF and/or pan-RAF inhibitors. In a further embodiment, methods and composition for the identification of novel agents useful to overcome resistance to BRAF and/or pan-RAF inhibitors are disclosed. The present invention also provides isolated polynucleotide sequences of novel 5′ BRAF splice variant(s) and proteins produced from such polynucleotide sequences as well as cell line(s) that endogenously or exogenously express the splice variant(s).
Novel Macrocycles And Uses Thereof
US Patent:
2002009, Jul 11, 2002
Filed:
Aug 24, 2001
Appl. No.:
09/938754
Inventors:
Samuel Danishefsky - Englewood NJ, US
Robert Garbaccio - Lansdale PA, US
Daniel Baeschlin - Arlesheim, CH
Shawn Stachel - Perkasie PA, US
David Solit - New York NY, US
Neal Rosen - Englewood NJ, US
Robert Garbaccio - Lansdale PA, US
Daniel Baeschlin - Arlesheim, CH
Shawn Stachel - Perkasie PA, US
David Solit - New York NY, US
Neal Rosen - Englewood NJ, US
International Classification:
C07D313/20, A61K031/335
US Classification:
514/450000, 549/269000
Abstract:
The present invention relates to compounds having the structure (I) (and pharmaceutically acceptable derivatives thereof)
wherein R-R, Z, X, A-B, D-E, G-J, and K-L are as defined herein, the synthesis thereof and the use of these compounds as therapeutic agents.